Teleflex stock gets higher EPS guidance after Q2 results

Published on 10/05/2026 at 14:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teleflex stock was last at USD 124.12 on October 2, 2026, down 1.58 percent. Q2 revenue rose 28.9 percent to USD 570.3 million as EPS guidance increased.

Fotorealistische Reinraum-Fertigung von Kathetern bei einem Medizintechnik-Hersteller — Teleflex Inc. (US8793691069) zeigt eine sterile Reinraum-Produktionslinie für medizinische Kathetersysteme und Schläuche fotorealistisch, Illustration mit AI erstellt.

Teleflex stock (ISIN US8793691069) was last at USD 124.12 on the NYSE on October 2, 2026, down 1.58 percent from the prior close of USD 126.11. The medical technology company enters October with higher 2026 adjusted EPS guidance, while its revenue outlook has narrowed after second-quarter integration pressures.

EPS guidance moves higher

Teleflex reported second-quarter 2026 revenue of USD 570.3 million, up 28.9 percent from the prior-year period, while adjusted EPS rose 1.7 percent to USD 1.76, according to the Yahoo Finance transcript dated August 6, 2026. The figures combine stronger Vascular and Surgical performance with weaker Interventional results during the Vascular Intervention integration.

For fiscal 2026, management raised adjusted EPS guidance to USD 6.90-7.20 from USD 6.25-6.55, but reduced pro forma adjusted constant-currency revenue growth guidance to 3.5-4.5 percent from 4.5-5.5 percent, the Yahoo Finance transcript shows. The contrast matters: cost reduction, share repurchases and lower interest expense support earnings, while integration timing constrains sales growth.

Integration remains the counter-factor

Teleflex reported adjusted operating margin of 19.6 percent in Q2 2026, down 520 basis points year over year, as tariffs, higher operating expenses and the acquired Vascular Intervention business weighed on profitability, according to Yahoo Finance. Interventional revenue fell 1 percent to USD 211.9 million, while Vascular revenue increased 8 percent to USD 246.3 million and Surgical revenue advanced 9.2 percent to USD 112.1 million.

The analyst backdrop turned more constructive after the results. Bank of America upgraded Teleflex to Buy from Neutral and lifted its price target to USD 158 from USD 145 on September 28, 2026, as reported by MarketBeat. The same source lists a Moderate Buy consensus from 12 analysts and an average target of USD 155.20.

Stock stays below yearly high

Teleflex stock was last at USD 124.12 on October 2, 2026, at 4:00 p.m. ET, placing it 14.4 percent below its 52-week high of USD 145.00 and above its 52-week low of USD 100.18. Market capitalization stood at USD 5.5 billion, with 574,682 shares traded on that date.